Sumitomo dainippon pharma oncology:Sumitomo Pharma Oncology

Sumitomo Pharma Oncology

Sumitomo Pharma Oncology

Ourrobustanddiversepipelinespansmultipleareas,includingoncogenicpathways,survivalmechanismsandnovelproteininteractions,whichaimtoaddress ...。其他文章還包含有:「AboutUs」、「ContactUs」、「LeadershipTeam」、「LifeatSMPOncology」、「News&Media」、「OurPipeline」、「rearrangementorNucleophosmin1(NPM1)Mutation」、「SumitomoDainipponPharmaOncologyAnnouncesIts...」、「SumitomoPharmaOncology」

查看更多 離開網站

Provide From Google
About Us
About Us

https://oncology.sumitomo-phar

Sumitomo Pharma Oncology is a global developer of novel cancer therapeutics with one goal: advancing purposeful science by transforming new discoveries into ...

Provide From Google
Contact Us
Contact Us

https://oncology.sumitomo-phar

Contact us. Sumitomo Pharma Oncology. We are always interested in hearing from you. Please find contact information below the map, or complete the Inquiries ...

Provide From Google
Leadership Team
Leadership Team

https://oncology.sumitomo-phar

Leadership. A model for success. We are led by a team of passionate and respected experts with proven track records of success in drug discovery and ...

Provide From Google
Life at SMP Oncology
Life at SMP Oncology

https://oncology.sumitomo-phar

If you want to have an impact on the lives of patients with cancer, take a look at Sumitomo Pharma Oncology (SMP Oncology). With our diverse pipeline, ...

Provide From Google
News & Media
News & Media

https://oncology.sumitomo-phar

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today ...

Provide From Google
Our Pipeline
Our Pipeline

https://oncology.sumitomo-phar

Discover our pipeline of targeted therapies. Sumitomo Pharma Oncology is advancing cancer treatments for novel pathways in solid tumors and hematologic ...

Provide From Google
rearrangement or Nucleophosmin 1 (NPM1) Mutation
rearrangement or Nucleophosmin 1 (NPM1) Mutation

https://oncology.sumitomo-phar

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of DSP-5336 in Patients with Acute Leukemia with and ...

Provide From Google
Sumitomo Dainippon Pharma Oncology Announces Its ...
Sumitomo Dainippon Pharma Oncology Announces Its ...

https://www.prnewswire.com

The merger of Tolero Pharmaceuticals and Boston Biomedical, and the formation of Sumitomo Dainippon Pharma Oncology, will help us achieve our ...

Provide From Google
Sumitomo Pharma Oncology
Sumitomo Pharma Oncology

https://oncology.sumitomo-phar

Sumitomo Pharma Oncology is a global developer of novel cancer therapeutics dedicated to the promise of purposeful science in oncology.